According to the Smart Finance APP, Wuxi BIO (02269) rose by up to 16%, up 13.3% at the time of publication, reporting HKD 12.44, with a turnover of HKD 1.238 billion.

It has been reported in the market that the newly released NDAA amendment list no longer includes the 8333 Biological Safety Act related to Wuxi BIO. The NDAA amendment list refers to the modification proposals or changes raised during the NDAA legislative process, which can affect the final content of the bill. Wuxi BIO previously strongly declared that the company has neither human genomics business nor collects human genomic data in any of its global business. The company stated that it has no security risks to the United States or any other country in the past, present, and future.

In addition, Wuxi BIO announced that it repurchased 1.81 million shares for HKD 19.9234 million yesterday, at a repurchase price of HKD 10.98-11.08 per share. As of March 22, 2024, the company has added 25 new projects this year. The company previously stated that it will actively explore the overseas market. It is reported that the "follow molecule" project of the company is progressing well and several potential heavyweight projects are progressing smoothly and will contribute considerable income in 2025 and beyond.